DLin-KC2-DMA - CAS 1190197-97-7

Catalog number: BRP-02119

DLin-KC2-DMA

DLin-KC2-DMA is a cationic/ionizable lipid for siRNA delivery. DLin-KC2-DMA was formulated and characterized in SNALP and demonstrated to have in vivo activity at siRNA doses as low as 0.01 mg/kg in rodents and 0.1 mg/kg in nonhuman primates.

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.
Ordering Information
Catalog Number Size Price Stock Quantity
BRP-02119 10 mg $298 In stock
Add to cart
Catalog
BRP-02119
Synonyms
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane; N,N-Dimethyl-2,2-di-(9Z,12Z)-9,12-octadecadien-1-yl-1,3-dioxolane-4-ethanamine; 2,2-Dilinoleyl-4-(2-dimethylaminoethyl)-1,3-dioxolane; 2-[2,2-Di-(9Z,12Z)-octadeca-9,12-dienyl-1,3-dioxolan-4-yl]-N,N-dimethylethanamine; DLin-K-XTC2-DMA; Dlin-KC2-DMA; D-Lin-KC2-DMA; XTC; XTC (synthetic lipid)
CAS
1190197-97-7
IUPAC Name
2-[2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-N,N-dimethylethanamine
Molecular Weight
642.09
Molecular Formula
C43H79NO2
Canonical SMILES
CCCCCC=CCC=CCCCCCCCCC1(OCC(O1)CCN(C)C)CCCCCCCCC=CCC=CCCCCC
InChI
InChI=1S/C43H79NO2/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-38-43(45-41-42(46-43)37-40-44(3)4)39-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h13-16,19-22,42H,5-12,17-18,23-41H2,1-4H3/b15-13-,16-14-,21-19-,22-20-
InChIKey
LRFJOIPOPUJUMI-KWXKLSQISA-N
Boiling Point
668.1±40.0 °C at 760 mmHg
Purity
>98%
Density
0.885±0.06 g/cm3
Solubility
Soluble in Ethanol, DMSO, DMF
Appearance
Colorless to light yellow liquid
Storage
Store at -20 °C
Formulation
May be formulated in DMSO
Related CAS
1224373-32-3 (S-isomer) 1224373-36-7 (R-isomer)

Chemical Structure:

Reference Reading

1. Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA
Jayesh A Kulkarni, Johnathan Layne Myhre, Sam Chen, Yuen Yi C Tam, Adrian Danescu, Joy M Richman, Pieter R Cullis. Nanomedicine. 2017 May;13(4):1377-1387. doi: 10.1016/j.nano.2016.12.014.
Lipid nanoparticles (LNPs) containing distearoylphosphatidlycholine (DSPC), and ionizable amino-lipids such as dilinoleylmethyl-4-dimethylaminobutyrate (DLin-MC3-DMA) are potent siRNA delivery vehicles in vivo. Here we explore the utility of similar LNP systems as transfection reagents for plasmid DNA (pDNA). It is shown that replacement of DSPC by unsaturated PCs and DLin-MC3-DMA by the related lipid DLin-KC2-DMA resulted in highly potent transfection reagents for HeLa cells in vitro. Further, these formulations exhibited excellent transfection properties in a variety of mammalian cell lines and transfection efficiencies approaching 90% in primary cell cultures. These transfection levels were equal or greater than achieved by Lipofectamine, with much reduced toxicity. Finally, microinjection of LNP-eGFP into the limb bud of a chick embryo resulted in robust reporter-gene expression. It is concluded that LNP systems containing ionizable amino lipids can be highly effective, non-toxic pDNA delivery systems for gene expression both in vitro and in vivo.
2. Rational design of cationic lipids for siRNA delivery
Sean C Semple, Akin Akinc, Jianxin Chen, Ammen P Sandhu, Barbara L Mui, Connie K Cho, Dinah W Y Sah, Derrick Stebbing, Erin J Crosley, Ed Yaworski, Ismail M Hafez, J Robert Dorkin, June Qin, Kieu Lam, Kallanthottathil G Rajeev, Kim F Wong, Lloyd B Jeffs, Lubomir Nechev, Merete L Eisenhardt, Muthusamy Jayaraman, Mikameh Kazem, Martin A Maier, Masuna Srinivasulu, Michael J Weinstein, Qingmin Chen, Rene Alvarez, Scott A Barros, Soma De, Sandra K Klimuk, Todd Borland, Verbena Kosovrasti, William L Cantley, Ying K Tam, Muthiah Manoharan, Marco A Ciufolini, Mark A Tracy, Antonin de Fougerolles, Ian MacLachlan, Pieter R Cullis, Thomas D Madden, Michael J Hope. Nat Biotechnol. 2010 Feb;28(2):172-6. doi: 10.1038/nbt.1602.
We adopted a rational approach to design cationic lipids for use in formulations to deliver small interfering RNA (siRNA). Starting with the ionizable cationic lipid 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), a key lipid component of stable nucleic acid lipid particles (SNALP) as a benchmark, we used the proposed in vivo mechanism of action of ionizable cationic lipids to guide the design of DLinDMA-based lipids with superior delivery capacity. The best-performing lipid recovered after screening (DLin-KC2-DMA) was formulated and characterized in SNALP and demonstrated to have in vivo activity at siRNA doses as low as 0.01 mg/kg in rodents and 0.1 mg/kg in nonhuman primates. To our knowledge, this represents a substantial improvement over previous reports of in vivo endogenous hepatic gene silencing.
3. In vivo delivery of plasmid DNA by lipid nanoparticles: the influence of ionizable cationic lipids on organ-selective gene expression
Azizah Algarni, Emily H Pilkington, Estelle J A Suys, Hareth Al-Wassiti, Colin W Pouton, Nghia P Truong. Biomater Sci. 2022 May 31;10(11):2940-2952. doi: 10.1039/d2bm00168c.
Ionizable cationic lipids play a critical role in developing new gene therapies for various biomedical applications, including COVID-19 vaccines. However, it remains unclear whether the formulation of lipid nanoparticles (LNPs) using DLin-MC3-DMA, an optimized ionizable lipid clinically used for small interfering RNA (siRNA) therapy, also facilitates high liver-selective transfection of other gene therapies such as plasmid DNA (pDNA). Here we report the first investigation into pDNA transfection efficiency in different mouse organs after intramuscular and intravenous administration of lipid nanoparticles (LNPs) where DLin-MC3-DMA, DLin-KC2-DMA or DODAP are used as the ionizable cationic lipid component of the LNP. We discovered that these three benchmark lipids previously developed for siRNA delivery followed an unexpected characteristic rank order in gene expression efficiency when utilized for pDNA. In particular, DLin-KC2-DMA facilitated higher in vivo pDNA transfection than DLin-MC3-DMA and DODAP, possibly due to its head group pKa and lipid tail structure. Interestingly, LNPs formulated with either DLin-KC2-DMA or DLin-MC3-DMA exhibited significantly higher in vivo protein production in the spleen than in the liver. This work sheds light on the importance of the choice of ionizable cationic lipid and nucleic acid cargo for organ-selective gene expression. The study also provides a new design principle towards the formulation of more effective LNPs for biomedical applications of pDNA, such as gene editing, vaccines and immunotherapies.
Related Products
Online Inquiry
Verification code
Inquiry Basket